tiprankstipranks
Trending News
More News >

Theriva Biologics Presents Promising VCN-01 Study Results

Story Highlights
Theriva Biologics Presents Promising VCN-01 Study Results

Don’t Miss TipRanks’ Half-Year Sale

Theriva Biologics ( (TOVX) ) has shared an announcement.

Theriva Biologics announced the results of a Phase 1 study on VCN-01, an oncolytic adenovirus, in refractory retinoblastoma patients. The study, presented at the 2025 ASCO annual meeting, showed that VCN-01 was well tolerated with no significant toxicities, and demonstrated promising antitumor activity, avoiding eye enucleation in some cases.

The most recent analyst rating on (TOVX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Average Trading Volume: 910,040

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.82M

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1